Describe an algorithm to investigate and treat an elderly male with lower urinary tract symptoms

LUTS in older men are grouped as storage (frequency, urgency, nocturia, urgency incontinence), voiding (hesitancy, weak or intermittent stream, straining, terminal dribble, incomplete emptying) and post-micturition (post-void dribble, sensation of incomplete emptying).

LUTS ≠ BPH. Symptoms may arise from the bladder (overactivity, underactivity), prostate, urethra, or systemic disease. Prevalence of BPH-related symptoms approaches 50% in multinational surveys of older men.

History — symptom pattern and duration; the most bothersome symptom; fluid, caffeine, alcohol; nocturia pattern; and specific pointers:

Type 2 diabetes with nocturia and polyuria >3 L → osmotic diuresis or neuropathic bladder

Neurological symptoms → neurogenic bladder

Gross haematuria or suprapubic pain → bladder tumour or calculus

Urethral trauma, urethritis or instrumentation → stricture

Family history of BPH or prostate cancer

Anticholinergic or sympathomimetic drugs impairing bladder function or raising outflow resistance

Quantify with IPSS/AUA-SI (mild 0–7, moderate 8–19, severe 20–35) plus the quality-of-life question. The score measures severity, not aetiology.

Examination — abdominal (palpable bladder), digital rectal examination for prostate size, consistency, nodules and sphincter tone, plus focused neurological examination; assess cognition, mobility and general fitness for any future procedure.

Bladder diary for 3 days — separates nocturnal polyuria and excessive fluid intake from true bladder dysfunction.

Urinalysis in every patient — detects infection and haematuria. Urine cytology if predominantly irritative symptoms or haematuria, especially in a smoker.

Post-void residual by bladder ultrasound; uroflowmetry where available (Qmax <10 mL/s on a void >150 mL is abnormal).

Serum creatinine (mg/dL) — not required routinely by AUA guidance in uncomplicated LUTS, but mandatory if there is retention, suspected obstructive uropathy, or planned surgery. Renal ultrasound if creatinine is raised or hydronephrosis suspected.

PSA (ng/mL) after shared decision-making in men with a life expectancy over 10 years; remember PSA is not cancer-specific, rises with BPH, prostatitis and instrumentation, and 25% of prostate cancers have a PSA ≤4.0 ng/mL.

Red flags for urological referral: acute or chronic urinary retention, renal insufficiency due to obstruction, recurrent UTI, bladder stones, gross haematuria, suspicious DRE or raised PSA, previous pelvic surgery or radiotherapy, neurological disease, urethral stricture, or failure of medical therapy.

Advanced tests in this group: cystoscopy, upper-tract imaging, and multichannel urodynamics/pressure-flow study to distinguish true bladder outlet obstruction from detrusor underactivity before committing to surgery.

Mild symptoms (IPSS <7) or minimal bother → watchful waiting with lifestyle advice: evening fluid restriction, avoid caffeine and spicy food, review diuretics and their timing, timed/organised voiding, pelvic floor exercises, treat constipation, double voiding — with periodic review.

Moderate to severe symptoms with bother → medical therapy:

α-blocker (tamsulosin, alfuzosin, silodosin, terazosin, doxazosin) — fastest symptomatic relief within days to weeks; does not alter disease progression. Side effects in ~5–9%: dizziness, postural hypotension, asthenia, rhinitis, retrograde ejaculation.

5-α-reductase inhibitor (finasteride, dutasteride) if the prostate is enlarged (>30–40 mL) or PSA is raised — shrinks the gland by up to 30%, takes 3–6 months, and reduces the risk of acute retention and surgery.

Combination α-blocker + 5-ARI for prostate volume >40 mL — the MTOPS trial showed a 66% reduction in acute urinary retention versus 39% with α-blockade alone and 34% with 5-ARI alone. The α-blocker may be stopped after 6–9 months and restarted if symptoms recur.

Antimuscarinic or β3-agonist added for persistent storage symptoms only when PVR is not elevated; avoid in men with a history of retention or cognitive impairment.

Phytotherapy is not recommended by AUA guidance.

Minimally invasive therapy for moderate symptoms with a small-to-moderate gland in a man wishing to avoid major surgery — transurethral microwave thermotherapy and related energy-based office procedures; higher retreatment rates than TURP, and several weeks before improvement.

Surgery — indications: renal insufficiency from BPH, recurrent UTI, gross haematuria due to BPH, bladder stones, refractory retention, or LUTS refractory to medical therapy.

TURP remains the reference standard for glands under 80 mL, with immediate symptom and flow improvement; transurethral incision for small glands; laser enucleation (HoLEP/ThuLEP) and open or simple robotic prostatectomy for very large glands.

Ongoing review: reassess IPSS, PVR, renal function and adverse effects; treat comorbid contributors (heart failure, diabetes, sleep apnoea, constipation) and, in the frail, always balance symptom benefit against hypotension, falls and delirium risk.

Assess History, IPSS + QoL, DRE, bladder diary, Storage vs voiding vs mixed pattern examination

Test Urinalysis, PVR, ± uroflowmetry, ± Uncomplicated vs complicated creatinine, ± PSA

Triage Red flags present? (retention, renal failure, Yes → urology referral, cystoscopy, recurrent UTI, stones, haematuria, imaging, urodynamics abnormal DRE/PSA, neurological disease) 4a. Mild IPSS <7 or low bother Watchful waiting + lifestyle 4b. α-blocker → add 5-ARI if gland >40 mL → Review at 4–12 weeks Moderate/ add antimuscarinic/β3-agonist if storage severe symptoms persist and PVR normal

Failure Minimally invasive therapy or surgery Choose by gland size, comorbidity and (TURP / laser enucleation / PAE in selected patient preference men)

AUA LUTS/BPH Guideline Amendment 2023 (expanded into a three-part guideline in 2026) revised statements on combination therapy, photoselective vaporisation (PVP), water vapour thermal therapy, laser enucleation and — importantly — formally admitted prostatic artery embolisation (PAE) into the guideline for selected men.

The 2026 guideline reframes the whole pathway around bladder function preservation and shared decision-making, rather than a rigid escalation ladder, and stresses that LUTS/BPH is multifactorial with both storage and emptying components.

Urodynamics before prostate surgery is not mandatory — the UPSTREAM randomised trial (26 hospitals) showed a non-invasive pathway is non-inferior to routine urodynamics for symptom outcomes, supporting selective rather than routine use.

Minimally invasive surgical therapies (MISTs) — water vapour thermal therapy, prostatic urethral lift, temporary implantable devices and PAE — have expanded the options for frail older men unfit for anaesthesia, with the trade-off of higher retreatment rates.

Metabolic drivers recognised: obesity, insulin resistance and chronic prostatic inflammation are now emphasised as modifiable contributors to LUTS/BPH progression — directly relevant to the Indian metabolic-syndrome phenotype.

India: TURP and laser prostatectomy are covered under AB-PMJAY, with the Ayushman Vay Vandana Card extending cover to all citizens aged 70 and above irrespective of income since 2024.

LUTS = storage + voiding + post-micturition symptoms; not synonymous with BPH.

IPSS grades severity, never aetiology.

Urinalysis and PVR are the two investigations every man with LUTS needs.

Routine serum creatinine is not required in uncomplicated LUTS; it is mandatory if retention or obstruction is suspected.

MTOPS: combination therapy cut acute retention by 66% versus 39% (α-blocker) and 34% (5-ARI).

Surgery indications: retention, renal failure, recurrent UTI, stones, gross haematuria, refractory symptoms.

TURP is standard for glands <80 mL; laser enucleation for larger glands.

Routine pre-operative urodynamics is no longer required (UPSTREAM).